Subscribe To

Price Alert Latest News Economic Calendar News

IGMS / Medivir to report new and updated data from ongoing phase 2a HCC study as part of its Q3 report on Friday

Webcasted Conference Call on Friday, October 27, 2023 at 14.00 CET STOCKHOLM , Oct. 25, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today the company plans to report new and updated data from its ongoing phase 2a study with the candidate drug fostrox in combination with Lenvima® in advanced hepatocellular carcinoma (HCC). The data will focus on the 18 out of 21 total patients that have had a minimum follow-up of 12 weeks. Read More

Demo Live Account See Partner Details

Content Topics

Medivir

Report

Updated

Data

From

Ongoing

Phase

Study

Part

Friday

Stock

IGMS

Posted: Oct 25 2023, 02:46

Author Name: PRNewsWire

IGMS News

By PRNewsWire
October 25, 2023

Medivir to report new and updated data from ongoing phase 2a HCC study as part of its Q3 report on Friday

Webcasted Conference Call on Friday, October 27, 2023 at 14.00 CET STOCKHOLM , Oct. 25, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a ph

By PRNewsWire
September 14, 2023

Medivir to present at the Pareto Securities Healthcare Conference

STOCKHOLM, Sweden , Sept. 14, 2023 /PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innova

By PRNewsWire
September 1, 2023

Medivir Hosts Expert Perspectives Webcast on the Evolving Treatment Landscape and the Unique Treatment Challenges in HCC

STOCKHOLM , Sept. 1, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments fo

By PRNewsWire
August 23, 2023

Medivir to present at the Erik Penser Bank Company Event

STOCKHOLM , Aug. 23, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments fo

By Zacks Investment Research
August 3, 2023

IGM Biosciences, Inc. (IGMS) Reports Q2 Loss, Misses Revenue Estimates

IGM Biosciences, Inc. (IGMS) came out with a quarterly loss of $1.43 per share in line with the Zacks Consensus Estimate. This compares to loss of $1.

By Zacks Investment Research
June 23, 2023

Strength Seen in IGM Biosciences, Inc. (IGMS): Can Its 7.6% Jump Turn into More Strength?

IGM Biosciences, Inc. (IGMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might

By PRNewsWire
June 1, 2023

Medivir to present at the Redeye Growth Day

STOCKHOLM , June 1, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for

By PRNewsWire
May 30, 2023

Medivir to present at the ABGSC Life Science Summit

STOCKHOLM , May 30, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.